Sang-Woo Lee
Direttore/Membro del Consiglio presso Geneos Therapeutics, Inc.
Profilo
Sang-Woo Lee currently works at Korea Investment Partners Co., Ltd., as Managing Director and Geneos Therapeutics, Inc., as Director from 2021.
Posizioni attive di Sang-Woo Lee
Società | Posizione | Inizio |
---|---|---|
Korea Investment Partners Co., Ltd.
Korea Investment Partners Co., Ltd. Investment ManagersFinance Korea Investment Partners Co., Ltd(Korea Investment Partners). is a Private Equity/Venture Capital firm, a subsidiary of Korea Investment Holdings Co., Ltd. founded in 1986. Korea Investment Partners Co., Ltd. is headquartered in Seoul. | Investitore di Private Equity | 14/04/2014 |
Geneos Therapeutics, Inc.
Geneos Therapeutics, Inc. BiotechnologyHealth Technology Geneos Therapeutics, Inc. Develops and commercializes neo-antigen based personalized cancer therapies. The firm engages in developing personalized immunotherapies against tumor specific neoantigens which arise from gene mutations in cancerous cells. The company was founded by Niranjan Y. Sardesai in 2017 and is headquartered in Plymouth Meeting, PA. | Direttore/Membro del Consiglio | 03/03/2021 |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 2 |
---|---|
Korea Investment Partners Co., Ltd.
Korea Investment Partners Co., Ltd. Investment ManagersFinance Korea Investment Partners Co., Ltd(Korea Investment Partners). is a Private Equity/Venture Capital firm, a subsidiary of Korea Investment Holdings Co., Ltd. founded in 1986. Korea Investment Partners Co., Ltd. is headquartered in Seoul. | Finance |
Geneos Therapeutics, Inc.
Geneos Therapeutics, Inc. BiotechnologyHealth Technology Geneos Therapeutics, Inc. Develops and commercializes neo-antigen based personalized cancer therapies. The firm engages in developing personalized immunotherapies against tumor specific neoantigens which arise from gene mutations in cancerous cells. The company was founded by Niranjan Y. Sardesai in 2017 and is headquartered in Plymouth Meeting, PA. | Health Technology |
- Borsa valori
- Insiders
- Sang-Woo Lee